The Impact of Monosodium Glutamate on
PET/CT
PSMA
monosodium glutamate
salivary glands;
xerostomia
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
01
10
2020
accepted:
29
12
2020
pubmed:
30
1
2021
medline:
7
1
2022
entrez:
29
1
2021
Statut:
ppublish
Résumé
The prostate-specific membrane antigen (PSMA) has been targeted for PET imaging and radioligand therapy (RLT) in patients with prostate cancer. Xerostomia is a common side effect of RLT because of the high salivary gland uptake of PSMA radioligands. Here, we aimed to determine the impact of monosodium glutamate (MSG) administration on PSMA-radioligand biodistribution within healthy organs and tumor lesions by using
Identifiants
pubmed: 33509974
pii: jnumed.120.257931
doi: 10.2967/jnumed.120.257931
pmc: PMC9364769
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
gallium 68 PSMA-11
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1244-1251Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Nucl Med Mol Imaging. 2018 Feb;52(1):80-81
pubmed: 29391917
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
Bioorg Med Chem Lett. 2010 Jan 1;20(1):392-7
pubmed: 19897367
FEBS J. 2014 Jul;281(14):3228-42
pubmed: 24863754
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147
pubmed: 30151743
J Nucl Med. 2018 Dec;59(12):1865-1868
pubmed: 30097503
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Nucl Med. 2021 Jan;62(1):81-87
pubmed: 32385167
J Nucl Med. 2019 Oct;60(10):1388-1393
pubmed: 30850503
Oral Dis. 2018 Mar;24(1-2):198-201
pubmed: 29480611
Oncotarget. 2017 Jul 6;8(33):55094-55103
pubmed: 28903405
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
J Med Chem. 2016 Mar 24;59(6):2810-9
pubmed: 26930119
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
J Clin Endocrinol Metab. 1996 Jan;81(1):184-91
pubmed: 8550750
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3008-3017
pubmed: 32430583
J Nucl Med. 2020 Aug;61(8):1145-1152
pubmed: 31806776
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
J Clin Oncol. 2005 Jul 20;23(21):4591-601
pubmed: 15837970
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
EJNMMI Res. 2018 Jul 3;8(1):56
pubmed: 29971556
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S
pubmed: 28864615
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544
pubmed: 31440799
J Nucl Med. 2017 Mar;58(3):445-450
pubmed: 27660138
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
J Nucl Med. 2018 Aug;59(8):1172-1173
pubmed: 29903929
Molecules. 2019 Feb 11;24(3):
pubmed: 30754620
J Nucl Med. 2015 Feb;56(2):293-8
pubmed: 25613537
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484
J Nucl Med. 2019 Sep;60(9):1270-1276
pubmed: 30737300
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Physiol Behav. 2006 Dec 30;89(5):711-7
pubmed: 17028046
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963
Nucl Med Commun. 2017 Jan;38(1):91-98
pubmed: 27782913
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Am J Clin Nutr. 2011 Jun;93(6):1328-36
pubmed: 21471280